Energenesis Biomedical to Showcase at BIO International Convention 2025
Energenesis Biomedical Co., Ltd. (TWSE: 6657), a biotechnology firm focused on developing treatments that restore cellular energy, has announced its participation in the upcoming BIO International Convention 2025. This major event will be held from June 16 to June 19 in Boston, MA. Energenesis will be featured at Booth #1645 within the Taiwan Pavilion, where it plans to unveil its innovative ENERGI Platform and share updates on its investigational therapy for Parkinson’s disease (PD), known as ENERGI-F705PD, which is touted as a groundbreaking treatment with potential to modify the disease.
Key Features of ENERGI-F705PD
ENERGI-F705PD represents a pioneering oral sustained-release therapy currently under development for Parkinson’s disease, specifically targeting the disease’s underlying mechanisms. The company expects to release topline results from its Phase I trial involving healthy participants in September 2025, following the successful completion of participant recruitment. This therapy is designed to tackle the core issues associated with Parkinson’s by decreasing the aggregation of alpha-synuclein, boosting antioxidant levels, and enhancing dopamine production.
CEO’s Statement on Parkinson’s Disease Treatment
“We are excited to share the advancements of our ENERGI-F705PD program at BIO International 2025,” remarked Dr. Han-Min Chen, CEO of Energenesis Biomedical. “Parkinson’s disease presents numerous challenges and has considerable unmet needs. Our strategy is centered on restoring cellular energy and addressing critical aspects of the disease’s pathology, providing a potential solution that could alter the course of treatment for patients. We are eager to present our latest findings and seek partnerships that may expedite the development of this crucial therapy.”
Overview of ENERGI-F705PD’s Mechanism
ENERGI-F705PD is a novel small-molecule medication formulated for oral sustained release. It aims to boost cellular ATP production and enhance antioxidant defenses by leveraging various metabolic pathways, including purine salvage, glycolysis, and the pentose phosphate pathway. This comprehensive approach directly targets significant pathological features of Parkinson’s disease.
Benefits of ENERGI-F705PD
One of the key benefits of ENERGI-F705PD is its potential to reduce and prevent the aggregation of α-synuclein. Increased ATP levels serve as a hydrotrope, mitigating the intracellular accumulation of misfolded α-synuclein, which is a primary factor in PD’s progression. Additionally, the therapy promotes antioxidant capabilities by stimulating the pentose phosphate pathway (PPP), leading to greater NADPH production, thereby fortifying the cellular antioxidant system. Furthermore, by optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD enhances the expression and activity of tyrosine hydroxylase (TH), a critical enzyme involved in dopamine synthesis, ultimately aiding in the restoration of neurotransmitter levels in the brains of individuals suffering from Parkinson’s disease.
About Energenesis Biomedical
Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a biopharmaceutical company in the clinical development phase, committed to creating innovative therapies that restore cellular energy and stimulate natural repair mechanisms. By integrating proprietary small-molecule innovations with AI-assisted drug repurposing, Energenesis Biomedical strives to expedite the development of solutions for unmet medical needs across a range of therapeutic fields, including neurodegenerative diseases, chronic wounds, and rare disorders. The company boasts a diverse pipeline that includes:
– ENERGI-F705PD: Oral tablet for Parkinson’s disease (Phase I)
– ENERGI-F703DFU: Gel for diabetic foot ulcers (Phase III)
– ENERGI-F701: Tonic for alopecia (Phase II completed)
– ENERGI-F703EB: Cream for epidermolysis bullosa (EB), which has received FDA Orphan Drug and Rare Pediatric Disease designations, as well as EMA orphan designation (preparing for Phase II)
